Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lung Therapeutics
Austin, Texas, United Statesaileronrx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Lung Therapeutics developed a pipeline of novel therapies targeting life-threatening and underserved lung conditions, with a focus on fibrotic diseases. Its lead asset LTI‑03 targets idiopathic pulmonary fibrosis and was in Phase 1b clinical trials at the time of acquisition. Another key candidate, LTI‑01, addresses loculated pleural effusion. The company was acquired by Aileron Therapeutics in October 2023 to further advance these programs.
- Therapeutic areas
- PulmonologyRare Diseases
- Modalities
- Biological products (e.g., peptides)Plasminogen activatorsCAV1 modulators
- Industry
- Biotech
Beyond the preview
Go deeper on Lung Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lung Therapeutics.